This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): Neutroval, XM02 filgrastim, biosimilar TevaGrastim (EU), granulocyte colony-stimulating factor (G-CSF), Granix
Description: XM02 is a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer. XM02 was principally developed as a similar biological medicinal product to Neupogen, the trademark for filgrastim (G-CSF).
Deal Structure: Teva developed XM02 with a partner, BioGeneriX AG, which is a 100% daughter company of ratiopharm.
In March 2010, Teva Pharmaceutical Industries announced that it entered into a definitive agreement to acquire ratiopharm for an enterprise value of 3.625 billion euros. The acquisition was completed in August 2010.
Additional information available to subscribers only: